Literature DB >> 35669026

Radiological Reversibility of Incomplete Atypical Femoral Fracture with Cessation of Bisphosphonate: Including an Early Stage of Incomplete Fracture.

Soo Min Cha1, Hyun Dae Shin1, Seung Hoo Lee1, Jae Woo Shin1.   

Abstract

Background: We found some important early findings in simple radiographs under the bisphosphonate (BP) treatment through a retrospective study. Here, we report the degree of reversibility of the early findings before overt fracture and analyze the factors affecting the differences through a retrospective case-control study.
Methods: We retrospectively inspected the clinical charts of patients diagnosed with atypical femoral fracture (AFF) at our institute between March 2006 and September 2018. Among the 209 screened patients, 102 patients were ultimately divided into 3 categories: Category 1 was described as endosteal diffuse flaring (EDF, early IAFF); category 2 was typical IAFF, with a tiny/partial crack that was limited to less than half of the thickness of the cortex; and category 3 was IAFF with a crack through the entire cortex. Demographics, clinical factors, and three categories of incomplete atypical femoral fracture (IAFF) were analyzed to determine whether their radiological condition "improved" or "progressed" after cessation of BP via univariate and multivariate analyses.
Results: Thirty-three, 53, and 16 were classified as categories 1, 2, and 3, respectively. Groups 1 and 2 consisted of 79 patients whose IAFF on the side of interest improved and 23 patients whose IAFF progressed, respectively. The uni/multivariate analyses of the groups demonstrated that the total period of BP (odds ratio [OR] = 1.49) and period of cessation of BP (OR = 0.24) were significant variables. In addition, prophylactic treatment for a contralateral IAFF was a strong factor for progression of the incomplete lesion on the side of interest (OR = 25.99). The rate of progression was significantly higher in patients with a mean treatment period of 43 months or longer, and in those with a mean cessation period shorter than 1.2 months.
Conclusion: Early-stage IAFF was found to be a unique finding in simple radiographs before the typical features of AFF. This EDF (category 1) was definitively reversible to normal bone when administration of BP was stopped. In addition, a long period of BP treatment and recent cessation of BP adversely affected IAFF with respect to spontaneous healing. Level of Evidence: Level III, a retrospective case-control study. © Indian Orthopaedics Association 2022.

Entities:  

Keywords:  Atypical fracture; Bisphosphonate; Endosteal flaring; Incomplete; Reversibility

Year:  2022        PMID: 35669026      PMCID: PMC9123112          DOI: 10.1007/s43465-022-00639-y

Source DB:  PubMed          Journal:  Indian J Orthop        ISSN: 0019-5413            Impact factor:   1.033


  31 in total

1.  Bisphosphonates and atypical femoral fractures.

Authors:  Stuart L Silverman; Susan M Ott; Richard M Dell
Journal:  N Engl J Med       Date:  2010-09-09       Impact factor: 91.245

2.  Coronal bowing of the femur and tibia in Chinese: its incidence and effects on total knee arthroplasty planning.

Authors:  W P Yau; K Y Chiu; W M Tang; T P Ng
Journal:  J Orthop Surg (Hong Kong)       Date:  2007-04       Impact factor: 1.118

Review 3.  A proposal for an atypical femur fracture treatment and prevention clinical practice guideline.

Authors:  R Dell; D Greene
Journal:  Osteoporos Int       Date:  2018-04-19       Impact factor: 4.507

4.  A retrospective bicenter comparative study of surgical outcomes of atypical femoral fracture: Potential effect of teriparatide on fracture healing and callus formation.

Authors:  Won Chul Shin; Nam Hoon Moon; Jae Hoon Jang; Han Ul Seo; Kuen Tak Suh
Journal:  Bone       Date:  2019-08-06       Impact factor: 4.398

5.  Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy.

Authors:  K D Gu; B Ettinger; C D Grimsrud; J C Lo
Journal:  Osteoporos Int       Date:  2021-04-29       Impact factor: 4.507

6.  Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

Authors:  Matthew R Allen; Ken Iwata; Roger Phipps; David B Burr
Journal:  Bone       Date:  2006-06-12       Impact factor: 4.398

7.  Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy.

Authors:  Cherie Ying Chiang; Roger M D Zebaze; Ali Ghasem-Zadeh; Sandra Iuliano-Burns; Andrew Hardidge; Ego Seeman
Journal:  Bone       Date:  2012-10-13       Impact factor: 4.398

8.  Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

Authors:  R Eastell; I Barton; R A Hannon; A Chines; P Garnero; P D Delmas
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

9.  Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development.

Authors:  Hanxuan Li; Zhousheng Xiao; L Darryl Quarles; Wei Li
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

10.  Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?

Authors:  Joyce S B Koh; Seo Kiat Goh; Meng Ai Png; Ernest B K Kwek; Tet Sen Howe
Journal:  J Orthop Trauma       Date:  2010-02       Impact factor: 2.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.